These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

503 related articles for article (PubMed ID: 18181565)

  • 1. Multi-target-directed ligands to combat neurodegenerative diseases.
    Cavalli A; Bolognesi ML; Minarini A; Rosini M; Tumiatti V; Recanatini M; Melchiorre C
    J Med Chem; 2008 Feb; 51(3):347-72. PubMed ID: 18181565
    [No Abstract]   [Full Text] [Related]  

  • 2. Tacripyrines, the first tacrine-dihydropyridine hybrids, as multitarget-directed ligands for the treatment of Alzheimer's disease.
    Marco-Contelles J; León R; de los Ríos C; Samadi A; Bartolini M; Andrisano V; Huertas O; Barril X; Luque FJ; Rodríguez-Franco MI; López B; López MG; García AG; Carreiras Mdo C; Villarroya M
    J Med Chem; 2009 May; 52(9):2724-32. PubMed ID: 19374444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Looking for the link between plaques and tangles.
    Duyckaerts C
    Neurobiol Aging; 2004 Jul; 25(6):735-9; discussion 743-6. PubMed ID: 15165696
    [No Abstract]   [Full Text] [Related]  

  • 4. Chronic anticholinergic administration and Alzheimer disease.
    Brodsky MC
    Surv Ophthalmol; 2005; 50(3):290-1. PubMed ID: 15850818
    [No Abstract]   [Full Text] [Related]  

  • 5. Tangles precede plaques but don't cause them.
    Terry RD
    Neurobiol Aging; 2004 Jul; 25(6):741-2; discussion 743-6. PubMed ID: 15165697
    [No Abstract]   [Full Text] [Related]  

  • 6. Acetylcholinesterase is a senile plaque component that promotes assembly of amyloid beta-peptide into Alzheimer's filaments.
    Inestrosa NC; Alvarez A; Calderón F
    Mol Psychiatry; 1996 Nov; 1(5):359-61. PubMed ID: 9154226
    [No Abstract]   [Full Text] [Related]  

  • 7. So what if tangles precede plaques?
    Price JL; Morris JC
    Neurobiol Aging; 2004 Jul; 25(6):721-3; discussion 743-6. PubMed ID: 15165694
    [No Abstract]   [Full Text] [Related]  

  • 8. The transition metals copper and iron in neurodegenerative diseases.
    Rivera-Mancía S; Pérez-Neri I; Ríos C; Tristán-López L; Rivera-Espinosa L; Montes S
    Chem Biol Interact; 2010 Jul; 186(2):184-99. PubMed ID: 20399203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease.
    Siegel GJ; Chauhan NB; Feinstein DL; Li G; Larson EB; Breitner JC; Montine TJ
    Neurology; 2008 Jul; 71(5):383; author reply 383. PubMed ID: 18663190
    [No Abstract]   [Full Text] [Related]  

  • 10. Preparation of cyclo-phen-type ligands: chelators of metal ions as potential therapeutic agents in the treatment of neurodegenerative diseases.
    Boldron C; Van der Auwera I; Deraeve C; Gornitzka H; Wera S; Pitié M; Van Leuven F; Meunier B
    Chembiochem; 2005 Nov; 6(11):1976-80. PubMed ID: 16208731
    [No Abstract]   [Full Text] [Related]  

  • 11. [Therapy of Alzheimer disease].
    Kovács T
    Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of acetylcholinesterase, beta-amyloid aggregation, and NMDA receptors in Alzheimer's disease: a promising direction for the multi-target-directed ligands gold rush.
    Rosini M; Simoni E; Bartolini M; Cavalli A; Ceccarini L; Pascu N; McClymont DW; Tarozzi A; Bolognesi ML; Minarini A; Tumiatti V; Andrisano V; Mellor IR; Melchiorre C
    J Med Chem; 2008 Aug; 51(15):4381-4. PubMed ID: 18605718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Medicinal and chemical approaches to focused search of agents for treatment and therapy of Alzheimer disease].
    Bachurin SO
    Vopr Med Khim; 2001; 47(2):155-97. PubMed ID: 11450439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New presenilin 1 mutation with Alzheimer disease and Lewy bodies.
    Rosenberg RN
    Arch Neurol; 2005 Dec; 62(12):1808. PubMed ID: 16344337
    [No Abstract]   [Full Text] [Related]  

  • 15. Copper homeostasis and neurodegenerative disorders (Alzheimer's, prion, and Parkinson's diseases and amyotrophic lateral sclerosis).
    Gaggelli E; Kozlowski H; Valensin D; Valensin G
    Chem Rev; 2006 Jun; 106(6):1995-2044. PubMed ID: 16771441
    [No Abstract]   [Full Text] [Related]  

  • 16. Neuropathology in Alzheimer's disease: target of pharmacotherapy.
    Souder E
    J Am Acad Nurse Pract; 2005 Mar; Suppl():3-5. PubMed ID: 16033022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of kynurenines in disorders of the central nervous system: possibilities for neuroprotection.
    Vamos E; Pardutz A; Klivenyi P; Toldi J; Vecsei L
    J Neurol Sci; 2009 Aug; 283(1-2):21-7. PubMed ID: 19268309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Review of the Common Neurodegenerative Disorders: Current Therapeutic Approaches and the Potential Role of Bioactive Peptides.
    Singh K; Gupta JK; Kumar S; Soni U
    Curr Protein Pept Sci; 2024; 25(7):507-526. PubMed ID: 38561605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mitochondria and neurodegeneration.
    Petrozzi L; Ricci G; Giglioli NJ; Siciliano G; Mancuso M
    Biosci Rep; 2007 Jun; 27(1-3):87-104. PubMed ID: 17486441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Developing therapeutics for the diseases of protein misfolding.
    May BC; Govaerts C; Cohen FE
    Neurology; 2006 Jan; 66(2 Suppl 1):S118-22. PubMed ID: 16432139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.